Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.52 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | TDO2 | P48775 | 3/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127629 | 0.87 | IDO1 (0.46) | IDO1TDO2MAPK1HTR2AADRA1A | |
| Water SCHEMBL11878861 | 0.84 | IDO1 (0.44) | IDO1TDO2MAPK1HTR2AADRA1A | |
| Ammonia Solution, Strong SCHEMBL7282272 | 0.84 | IDO1 (0.44) | IDO1TDO2MAPK1HTR2AADRA1A | |
| Methane SCHEMBL29089947 | 0.84 | IDO1 (0.44) | IDO1TDO2MAPK1HTR2AADRA1A | |
| SCHEMBL9097250 | 0.81 | SMN1; SMN2 (0.50) | CHRNB2CHRNA4ACP3CYP3A4ALDH1A1 | |
| SCHEMBL16743446 | 0.81 | ACP3 (0.48) | CHRNB2CHRNA4ACP3CYP3A4ALDH1A1 | |
| SCHEMBL3924304 | 0.78 | IDO1 (0.47) | CYP3A4ALDH1A1IDO1TDO2TDP1 | |
| SCHEMBL10981079 | 0.78 | IDO1 (0.67) | ALDH1A1IDO1TDO2TDP1MEN1 | |
| SCHEMBL11500414 | 0.78 | LMNA (0.46) | IDO1TDO2MEN1HPGDHTR2A | |
| SCHEMBL3597509 | 0.78 | HTR2A (0.54) | ALDH1A1IDO1TDO2MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| EP-3645548-B1 | METHODS FOR PREPARING BILE ACIDS | MEDYTOX INC (KR) | 2023-11-29 | — | — | EP | disclosed |
| EP-3271468-B1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) | 2022-12-14 | — | — | EP | disclosed |
| CN-107849594-B | Deamination of organophosphorus nucleosides | 科技学专业学院有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-20220009957-A1 | Methods for Preparing Bile Acids | MEDYTOX INC. (KR) | 2022-01-13 | — | — | US | disclosed |
| US-11161872-B2 | Methods for preparing bile acids | MEDYTOX INC. (KR) | 2021-11-02 | — | — | US | disclosed |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | AMIRA THERAPEUTICS, S.L. (ES) | 2021-07-29 | — | — | US | disclosed |
| EP-3813832-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2021-05-05 | — | — | EP | disclosed |
| WO-2016146808-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S. A. (ES) | 2016-09-22 | — | — | WO | disclosed |
| US-9416084-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2016-08-16 | — | — | US | disclosed |
| US-20160107977-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2016-04-21 | — | — | US | disclosed |
| EP-3004036-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | Leo Laboratories Limited (IE) | 2016-04-13 | — | — | EP | disclosed |
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2015-11-05 | — | — | US | disclosed |
| WO-2014191457-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | LEO LABORATORIES LIMITED (IE) | 2014-12-04 | — | — | WO | disclosed |
| US-8901356-B2 | Method of producing ingenol-3-angelate | LEO LABORATORIES LIMITED (IE) | 2014-12-02 | — | — | US | disclosed |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | Hogberg, Thomas (DK) | 2013-07-11 | — | — | US | disclosed |
| EP-2595948-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010172-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO PHARMA A/S (DK) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315118-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | CHRNB2 3128/4885CHRNA4 3225/4885ACP3 258/4885 |
| US-20220009957-A1 | Methods for Preparing Bile Acids | DHCR7, CYP46A1, CYP27A1 | CHRNB2 3594/4885CHRNA4 4087/4885ACP3 134/4885 |
| US-20160107977-A1 | METHODS OF SYNTHESIS OF INGENOL AND INTERMEDIATES THEREOF | CYP51A1, ERG28, UTP20 | CHRNB2 3589/4885CHRNA4 3458/4885ACP3 1969/4885 |
| US-20130177952-A1 | METHOD OF PRODUCING INGENOL-3-ANGELATE | PRKAG3, AMPD3, ERG28 | CHRNB2 3128/4885CHRNA4 3225/4885ACP3 258/4885 |
| US-11161872-B2 | Methods for preparing bile acids | DHCR7, CYP46A1, CYP27A1 | CHRNB2 3594/4885CHRNA4 4087/4885ACP3 134/4885 |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | UGT1A3, UGT1A1, UGT1A6 | CHRNB2 3057/4885CHRNA4 3766/4885ACP3 91/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | CHRNB2 3057/4885CHRNA4 3766/4885ACP3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.